Effects of antiretroviral agents during pregnancy on liver enzymes and amylase in HIV-exposed, uninfected newborn infants.
This study assessed the effect of antiretroviral drugs administered to pregnant women on amylase and liver enzymes of the neonate. A prospective study was conducted on 52 neonates divided into three groups: infants born to HIV-infected mothers taking zidovudine (ZDV group, n = 18), infants born to mothers taking zidovudine + lamivudine + nelfinavir (TT group, n = 22) and infants born to normal women (control group, n = 12). Umbilical cord blood from the newborn infant was used to determine liver transaminases and amylase. Data were analyzed statistically by nonparametric tests, with the level of significance set at p<0.05. The median levels for TT group newborns were 33.3 U/L for oxaloacetic transaminase, 21.5 U/L for pyruvic transaminase, 1.9 mg/dL for total bilirubin, 153 mg/dL for alkaline phosphatase, and 9.6 U/L for amylase. These results did not differ from those obtained for Control newborns or newborns exposed to ZDV alone. No association was observed between the use of antiretroviral drugs during pregnancy and adverse effects on neonatal amylase and hepatic parameters at birth.
El Beitune
Patrícia
P
Department of Obstetrics and Gynecology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil. pbeitune@fffcmpa.edu.br
Duarte
Geraldo
G
Campbell
Oona
O
Quintana
Silvana Maria
SM
Rodrigues
Laura C
LC
D000293:Adolescent; D000328:Adult; D000681:Amylases / Q000097:blood*; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D035061:Control Groups; D004359:Drug Therapy, Combination; D005260:Female; D005312:Fetal Blood / Q000201:enzymology; D015658:HIV Infections / Q000188:drug therapy / Q000517:prevention & control* / Q000635:transmission; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D019259:Lamivudine / Q000627:therapeutic use; D008099:Liver / Q000187:drug effects / Q000201:enzymology*; D008297:Male; D019888:Nelfinavir / Q000627:therapeutic use; D011247:Pregnancy; D011446:Prospective Studies; D000637:Transaminases / Q000097:blood*; D015215:Zidovudine / Q000627:therapeutic use
D019380:Anti-HIV Agents; D019259:Lamivudine; D015215:Zidovudine; D000637:Transaminases; D000681:Amylases; D019888:Nelfinavir